HLA-E and myeloid sarcoma: Given that NK cytotoxicity was reported to be weaker in the presence of HLA-E in CSF and MS lesions [130], CD56bright NK immunoregulatory function might also be compromised in the context of MS tissue, as observed in the periphery.